Edition:
India

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

281.80DKK
16 Nov 2018
Change (% chg)

kr.0.60 (+0.21%)
Prev Close
kr.281.20
Open
kr.281.20
Day's High
kr.285.00
Day's Low
kr.277.00
Volume
437,940
Avg. Vol
379,731
52-wk High
kr.477.70
52-wk Low
kr.275.90

Chart for

About

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and... (more)

Overall

Beta: 0.84
Market Cap(Mil.): kr.76,330.01
Shares Outstanding(Mil.): 198.93
Dividend: 2.45
Yield (%): 0.64

Financials

  LUN.CO Industry Sector
P/E (TTM): 38.10 31.23 33.59
EPS (TTM): 10.07 -- --
ROI: 15.52 15.57 15.05
ROE: 20.33 16.94 16.62

UPDATE 1-Lundbeck shares slide as Danish drugmaker's new drugs disappoint

Nov 7 Shares in Lundbeck fell 5 percent on Wednesday after third-quarter sales of the Danish drugmaker's new drugs disappointed and it had to rely on its old line up to prop up revenues.

07 Nov 2018

Drug maker Lundbeck raises 2018 financial guidance

Nov 7 Danish drug maker Lundbeck raised its full-year financial guidance on Wednesday citing "better-than-expected sales performance".

07 Nov 2018

UPDATE 2-European stocks falter as pharma sector falls

* Sentiment still soured by tariff concerns (Adds detail and quote, updates prices at close)

08 Aug 2018

European shares dip as pharmaceuticals' earnings weigh

LONDON European shares dipped on Wednesday as poor corporate earnings in the pharmaceutical sector weighed on sentiment soured by trade tensions, with Washington preparing tariffs on another $16 billion of Chinese goods.

08 Aug 2018

UPDATE 1-Lundbeck drops as its adjusted profit outlook fails to impress

COPENHAGEN, Aug 8 Shares in Lundbeck dropped as much as 10 percent on Wednesday after the Danish drugmaker failed to impress the market with revisions to its full-year profit outlook.

08 Aug 2018

Lundbeck Q2 beats forecast, lifts 2018 guidance

COPENHAGEN, Aug 8 Danish drugmaker Lundbeck on Wednesday posted better than expected second quarter earnings and adjusted its full-year forecast to the upper end of the earlier guidance range.

08 Aug 2018

UPDATE 1-Drugmaker Lundbeck to settle U.S. charity probe for $52.6 mln

BOSTON, June 6 Danish drugmaker Lundbeck said on Wednesday that it will pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations.

07 Jun 2018

Drugmaker Lundbeck to settle U.S. charity probe for $52.6 mln

BOSTON, June 6 Danish drugmaker Lundbeck said on Wednesday that it had reached a deal to pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations.

07 Jun 2018

Earnings vs. Estimates